BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37141482)

  • 1. A Case of Progressive Cholestatic Drug-Induced Liver Injury Due to Terbinafine.
    Ley D; Musto J; Said A
    WMJ; 2023 May; 122(2):138-142. PubMed ID: 37141482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of HLA-A*33:01 in patients with cholestatic hepatitis attributed to terbinafine.
    Fontana RJ; Cirulli ET; Gu J; Kleiner D; Ostrov D; Phillips E; Schutte R; Barnhart H; Chalasani N; Watkins PB; Hoofnagle JH
    J Hepatol; 2018 Dec; 69(6):1317-1325. PubMed ID: 30138689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Terbinafine-induced prolonged cholestasis with reduction of interlobular bile ducts.
    Mallat A; Zafrani ES; Metreau JM; Dhumeaux D
    Dig Dis Sci; 1997 Jul; 42(7):1486-8. PubMed ID: 9246051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Terbinafine-associated hepatic injury.
    van 't Wout JW; Herrmann WA; de Vries RA; Stricker BH
    J Hepatol; 1994 Jul; 21(1):115-7. PubMed ID: 7963410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Terbinafine-induced hepatic failure requiring liver transplantation.
    Perveze Z; Johnson MW; Rubin RA; Sellers M; Zayas C; Jones JL; Cross R; Thomas K; Butler B; Shrestha R
    Liver Transpl; 2007 Jan; 13(1):162-4. PubMed ID: 17192859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent terbinafine-induced acute generalised exanthematous pustulosis and hepatitis.
    Carnio LR; Johnson Shaw ME; Schnur J; Casadesus D
    BMJ Case Rep; 2021 Jan; 14(1):. PubMed ID: 33462036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A curious case of cholestasis: oral terbinafine associated with cholestatic jaundice and subsequent erythema nodosum.
    Kumar K; Gill A; Shafei R; Wright JL
    BMJ Case Rep; 2014 Dec; 2014():. PubMed ID: 25480138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hepatitis attributed to the use of terbinafine].
    Boldewijn OY; Ottervanger JP; Mostart CM; Janssens AR; Calame J; Jonkers GJ
    Ned Tijdschr Geneeskd; 1996 Mar; 140(12):669-72. PubMed ID: 8668241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Terbinafine-induced cholestatic liver injury].
    Shiloah E; Horowiz M; Zecler E
    Harefuah; 1997 Jul; 133(1-2):11-2, 80-1. PubMed ID: 9332048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Terbinafine-induced liver injury.
    Kaushal M; Tolani P; Kumar N; Sharma S
    Natl Med J India; 2017; 30(6):321-323. PubMed ID: 30117442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Terbinafine-induced hepatic dysfunction.
    Chambers WM; Millar A; Jain S; Burroughs AK
    Eur J Gastroenterol Hepatol; 2001 Sep; 13(9):1115-8. PubMed ID: 11564966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis associated with terbinafine therapy: three case reports and a review of the literature.
    Gupta AK; del Rosso JQ; Lynde CW; Brown GH; Shear NH
    Clin Exp Dermatol; 1998 Mar; 23(2):64-7. PubMed ID: 9692307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Terbinafine-induced acute autoimmune hepatitis in the setting of hepatitis B virus infection.
    Paredes AH; Lewis JH
    Ann Pharmacother; 2007 May; 41(5):880-4. PubMed ID: 17426078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Terbinafine-induced hepatotoxicity.
    Mejías Manzano MLÁ; Giráldez Gallego Á; Ontanilla Clavijo G; Sousa Martín JM
    Gastroenterol Hepatol; 2019; 42(6):394-395. PubMed ID: 31167724
    [No Abstract]   [Full Text] [Related]  

  • 15. Terbinafine-associated hepatotoxicity.
    Ajit C; Suvannasankha A; Zaeri N; Munoz SJ
    Am J Med Sci; 2003 May; 325(5):292-5. PubMed ID: 12792250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Terbinafine-induced cholestatic liver disease.
    Lazaros GA; Papatheodoridis GV; Delladetsima JK; Tassopoulos NC
    J Hepatol; 1996 Jun; 24(6):753-6. PubMed ID: 8835752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydralazine-induced cholestatic hepatitis.
    Hassan A; Hammad R; Cucco R; Niranjan S
    Am J Ther; 2009; 16(4):371-3. PubMed ID: 19092641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Terbinafine and cholestatic hepatitis].
    Tejada García M; Llvona Hevia AM; Martín Arias L; García-Pando AC
    Med Clin (Barc); 1997 Sep; 109(9):356. PubMed ID: 9379769
    [No Abstract]   [Full Text] [Related]  

  • 19. Vanishing bile duct syndrome related to DILI and Hodgkin lymphoma overlap: A rare and severe case.
    Greca RD; Cunha-Silva M; Costa LBE; Costa JGF; Mazo DFC; Sevá-Pereira T; Nascimento MMC; Pereira IE; Oliveira FC; Faria GAS; Neto FLP; Almeida JRS
    Ann Hepatol; 2020; 19(1):107-112. PubMed ID: 31537508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Acute hepatitis associated with terbinafine].
    Vivas S; Rodríguez M; Palacio MA; Cadenas F; Lomo J; Rodrigo L
    Gastroenterol Hepatol; 1997 Nov; 20(9):456-8. PubMed ID: 9445740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.